ArticleAnnals of surgical oncology2025
Employment Disruption and Financial Burden Associated with Gastrointestinal Cancers.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Outcomes That Matter in Gastrointestinal Cancer Care: A Focus Group Study of Patient-Centred Outcomes Identified by Patients and Care Partners.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Prehabilitation and Postoperative Outcomes in Major Surgery: A Retrospective Cohort Study Using MarketScan Claims Data.World journal of surgery · 2026Article
- Following Gastrointestinal Surgery for Cancer: How Patients Pursue Surgical Treatment.Behavioral sciences (Basel, Switzerland) · 2026Article
- Distinct financial and social hardships among gastrointestinal cancer survivors: a national survey analysis.Journal of cancer survivorship : research and practice · 2026Article
- ASO Author Reflections: Employment Disruption and Financial Burden Associated with Gastrointestinal Cancers.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the extent of employment disruption and the financial strain faced by individuals with GI cancer is crucial to develop targeted support services. We sought to investigate employment disruption and financial burden among patients with gastrointestinal cancer (GI) diagnosis.
methodsPatients diagnosed with GI cancer were identified using the MarketScan database. Multivariable Cox proportional hazards models were used to evaluate the risk of employment disruption among patients with a GI cancer diagnosis.
resultsA total of 11,832 individuals with GI cancer were included. Median patient age was 54 years (IQR: 49-59) with a majority of patients being male (n=7054; 59.6%). In the year following a GI cancer diagnosis, 13.8% (n=1638) of patients experienced employment disruption. Notably, individuals working in finance (HR 1.66, 95% CI 1.37-2.02), manufacturing (HR 1.19, 95% CI 1.01-1.42), and the transportation industry (HR 1.33, 95% CI 1.11-1.60) were at a higher risk of experiencing employment disruption. Patients with GI cancer had higher out-of-pocket (OOP) costs ($3250 [IQR: $1756-$5,255] vs. $453 [IQR: $142-$1189]), more workdays missed (50 [IQR: 28-$72] vs. 5 [IQR: 2-10]) (both p < 0.001) and a threefold higher risk of employment disruption (HR 3.16, 95% CI 2.96-3.38) compared with individuals without a GI cancer diagnosis.
conclusionPatients with GI cancer are three times more likely to experience employment disruption and face significant financial burdens. Targeted measures, such as flexible work arrangements, job protection policies, and access to vocational rehabilitation services, are needed for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.